Skip Navigation



Annals of Oncology Advance Access published online on July 20, 2005
Annals of Oncology, doi:10.1093/annonc/mdi317
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/10/1702    most recent
mdi317v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dresemann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dresemann, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received March 9, 2005
Revised June 6, 2005
Accepted June 9, 2005

Original article

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

G. Dresemann 1*

1 Franz-Hospital, Onkologische Abteilung, Dülmen, Germany

* To whom correspondence should be addressed.
G. Dresemann, E-mail: gdresemann{at}aol.com


  Abstract

Background: Grade IV malignancies of the brain, such as glioblastoma multiforme (GBM), are associated with a dismal prognosis. Autocrine and paracrine loops of platelet-derived growth factor (PDGF) signaling, as well as other signal transduction pathways, have been postulated to play a role in glioblastoma transformation, and molecules involved in these pathways can potentially serve as targets for therapeutic inhibitory agents. Imatinib, an inhibitor of PDGF receptors {alpha} and {beta}, as well as other selected tyrosine kinases, is indicated for treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). Unfortunately, imatinib, as with many conventional chemotherapeutic agents, has limited efficacy as monotherapy in GBM. In preclinical studies, the chemotherapeutic agent hydroxyurea is demonstrated to have cytotoxic effects additive with imatinib.

Patients and methods: We tested the combination of hydroxyurea and imatinib in 30 grade IV progressive GBM patients refractory to chemo- and radiotherapy. All 30 patients were evaluable after a median 19 weeks observation time.

Results: Combination therapy with imatinib and hydroxyurea resulted in a 20% response rate, including complete and partial responses. Patients experiencing response or stable disease yielded a combined clinical benefit rate of 57%. Median time to progression was 10 weeks and median overall survival was 19 weeks. Three patients continue to survive on combination therapy, with the shortest duration being 106 weeks. Six-month and 2-year progression-free survival rates were 32% and 16%, respectively.

Conclusion: The efficacy results, combined with findings that imatinib and hydroxyurea were well tolerated, suggest that this combination shows promise as therapy for GBM.

Keywords: efficacy; glioblastoma multiforme; hydroxyurea; imatinib; PDGFRs; safety.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Oncologist, June 1, 2009; 14(6): 621 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Benny, L. G. Menon, G. Ariel, E. Goren, S.-K. Kim, C. Stewman, P. M. Black, R. S. Carroll, and M. Machluf
Local Delivery of Poly Lactic-co-glycolic Acid Microspheres Containing Imatinib Mesylate Inhibits Intracranial Xenograft Glioma Growth
Clin. Cancer Res., February 15, 2009; 15(4): 1222 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Raymond, A. A. Brandes, C. Dittrich, P. Fumoleau, B. Coudert, P. M.J. Clement, M. Frenay, R. Rampling, R. Stupp, J. M. Kros, et al.
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
J. Clin. Oncol., October 1, 2008; 26(28): 4659 - 4665.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Martinez-Rojano, J. Mancilla-Ramirez, L. Quinonez-Diaz, and N. Galindo-Sevilla
Activity of Hydroxyurea against Leishmania mexicana
Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3642 - 3647.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
Oncologist, September 1, 2008; 13(9): 978 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
D. A. Reardon, A. Desjardins, J. J. Vredenburgh, S. Sathornsumetee, J. N. Rich, J. A. Quinn, T. F. Lagattuta, M. J. Egorin, S. Gururangan, R. McLendon, et al.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma
Neuro-oncol, January 1, 2008; 10(3): 330 - 340.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke
Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer
Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Bihorel, G. Camenisch, G. Gross, M. Lemaire, and J.-M. Scherrmann
Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier
Drug Metab. Dispos., December 1, 2006; 34(12): 1945 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
M. Puputti, O. Tynninen, H. Sihto, T. Blom, H. Maenpaa, J. Isola, A. Paetau, H. Joensuu, and N. N. Nupponen
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas
Mol. Cancer Res., December 1, 2006; 4(12): 927 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Y. Wen, W.K. A. Yung, K. R. Lamborn, P. L. Dahia, Y. Wang, B. Peng, L. E. Abrey, J. Raizer, T. F. Cloughesy, K. Fink, et al.
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08.
Clin. Cancer Res., August 15, 2006; 12(16): 4899 - 4907.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. De Vita, S. De Matteis, L. Laurenti, P. Chiusolo, F. Sora, N. Piccirillo, G. Reddiconto, A. Fiorini, G. Leone, and S. Sica
Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM
Ann. Onc., April 1, 2006; 17(4): 720 - 721.
[Full Text] [PDF]

Home page
 The OncologistHome page
D. A. Reardon and P. Y. Wen
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Oncologist, February 1, 2006; 11(2): 152 - 164.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.